Cell cycle related proteins as prognostic parameters in radically resected non-small cell lung cancer. Issue 7 (23rd June 2005)

• Record Type: Journal Article
• Authors: Esposito, V; Baldi, A; De Luca, A; Tonini, G; Vincenzi, B; Santini, D; Persichetti, P; Mancini, A; Citro, G; Baldi, F; Groeger, A M; Caputi, M
• Is Part Of: Journal of clinical pathology. Volume 58:Issue 7(2005)
• Page Start: 734
• Page End: 739
• Publication Date: 2005-06-23
• Subjects: CI, confidence interval -- NSCLC, non-small cell lung cancer -- PCNA, proliferating nuclear cell antigen -- pRb, retinoblastoma protein; non-small cell lung cancer -- p53 -- pRb2/p130 -- p16 -- cyclin D1 -- immunohistochemistry -- prognosis; Pathology -- Periodicals; Pathology, Molecular -- Periodicals; 616.0705
• DOI: 10.1136/jcp.2004.023531
• Languages: English
• ISSNs: 0021-9746

Abstract

Abstract : Background: Experimental evidence suggests that lung cancer development and progression can be linked to an increased proliferation rate. Aims/Methods: To evaluate the immunohistochemical expression of seven components of the cell cycle machinery in a series of well characterised non-small cell lung cancer (NSCLC) specimens (n = 105). Results: Multivariate analysis revealed that simultaneous loss of expression of three of these factors—cyclin D1, the cyclin dependent kinase inhibitor p16, and the tumour suppressor retinoblastoma protein Rb2/p130—correlated with survival, confirming the hypothesis that the cyclin D1–p16–retinoblastoma tumour suppressor pathway is inactivated in most lung cancer samples. Conclusions: These results suggest that loss of control of cell cycle checkpoints is a common occurrence in lung cancer and support the idea that functional cooperation between different cell cycle regulatory proteins constitutes another level of regulation in cell growth control and tumour suppression.